Roche has bolstered its early-stage pipeline by entering a collaboration with small US biotech company Inovio Pharmaceuticals. Roche is paying $10m upfront for exclusive worldwide rights to two of Inovio's preclinical immunotherapies targeting prostate cancer and hepatitis B.
Roche's license covers Inovio's DNA-based vaccines INO-5150 (targeting prostate cancer) and INO-1800 (targeting hepatitis B) as well as the use...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
